13-Nov-2025 12:00 AM CST - Business Wire Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced its business update and financial results for the first nine months of 2025. This quarter highlights strong execution across our key programs, said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. With FDA clearance to initiate TELLOMAK-3, we are advancing lacutamab toward its confirmatory Phase 3 and potential accelerated approval
5-Nov-2025 12:00 AM CST - Business Wire Innate Pharma Announces Conference Call and Webcast for Third Quarter 2025 Results and Business Updates #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that the Company will hold a conference call on Thursday, November 13, 2025, at 2 p.m. CET / 8 a.m. ET, to give an update on business progress during the third quarter of 2025. Participants during the call will be: Jonathan Dickinson, Chief Executive Officer Sonia Quaratino, Executive Vice President, Chief Medical Officer Yannis Morel, Executive V
13-May-2025 12:00 AM CST - Business Wire Innate Pharma Reports First Quarter 2025 Business Update and Financial Results #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today reported its consolidated financial results for the quarter ending March 31, 2025. The first quarter of 2025 was marked by significant progress across both our pipeline and strategic partnerships, said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. Sanofis 15 million equity investment reflects our shared conviction in the potential of ou
13-May-2025 12:00 AM CST - Business Wire Innate Pharma fait le point sur ses activits et publie ses rsultats financiers pour le premier trimestre 2025 #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris : IPH ; Nasdaq: IPHA) ( Innate ou la Socit ) annonce aujourdhui son chiffre daffaires et sa position de trsorerie pour les trois premiers mois de lanne 2025. Le premier trimestre 2025 a t marqu par des progrs significatifs sur l'ensemble de notre portefeuille et nos partenariats stratgiques, commente Jonathan Dickinson, Prsident du Directoire d'Innate Pharma. La prise de participation de 15 mil
27-Mar-2025 1:00 AM CST - Business Wire Innate Pharma Reports Full Year 2024 Financial Results and Business Update #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today reported its consolidated financial results for the year ending December 31, 2024. The consolidated financial statements are attached to this press release. Our strategy is clear: drive innovation through our ANKET NK-cell engager platform and accelerate our ADC programs. We are making strong clinical progress, with our lead proprietary ANKET, IPH6501 ad
10-Jan-2025 12:00 AM CST - Business Wire Innate Pharma Announces Transformative Strategy to Accelerate Growth #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced its updated strategy for company growth. This comprehensive plan is anchored in three key pillars designed to drive sustainable growth, foster innovation, and deliver transformative therapies to patients worldwide. "Our updated strategy underscores Innate Pharmas unwavering dedication to innovation, collaboration, and delivering transformative th
20-Dec-2024 12:00 AM CST - Business Wire Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that its management will present and host 1x1 meetings at the 43rd Annual J.P. Morgan Healthcare Conference being held on January 13-16, 2025 in San Francisco, CA. Jonathan Dickinson, Chief Executive Officer of Innate Pharma, will represent the Company in a session scheduled Tuesday, January 14, 2025 from 11:15 - 11:55 am PST. Other Executive Boar
13-Nov-2024 12:00 AM CST - Business Wire Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced its business update and financial results for the first nine months of 2024. "Im honored to join Innate Pharma at such a pivotal moment in its evolution, said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. We achieved notable regulatory milestones during the quarter including encouraging initial feedback from the FDA for lacutama
13-Nov-2025 12:00 AM CST - Business Wire Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced its business update and financial results for the first nine months of 2025. This quarter highlights strong execution across our key programs, said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. With FDA clearance to initiate TELLOMAK-3, we are advancing lacutamab toward its confirmatory Phase 3 and potential accelerated approval
5-Nov-2025 12:00 AM CST - Business Wire Innate Pharma Announces Conference Call and Webcast for Third Quarter 2025 Results and Business Updates #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that the Company will hold a conference call on Thursday, November 13, 2025, at 2 p.m. CET / 8 a.m. ET, to give an update on business progress during the third quarter of 2025. Participants during the call will be: Jonathan Dickinson, Chief Executive Officer Sonia Quaratino, Executive Vice President, Chief Medical Officer Yannis Morel, Executive V
13-May-2025 12:00 AM CST - Business Wire Innate Pharma Reports First Quarter 2025 Business Update and Financial Results #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today reported its consolidated financial results for the quarter ending March 31, 2025. The first quarter of 2025 was marked by significant progress across both our pipeline and strategic partnerships, said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. Sanofis 15 million equity investment reflects our shared conviction in the potential of ou
13-May-2025 12:00 AM CST - Business Wire Innate Pharma fait le point sur ses activits et publie ses rsultats financiers pour le premier trimestre 2025 #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris : IPH ; Nasdaq: IPHA) ( Innate ou la Socit ) annonce aujourdhui son chiffre daffaires et sa position de trsorerie pour les trois premiers mois de lanne 2025. Le premier trimestre 2025 a t marqu par des progrs significatifs sur l'ensemble de notre portefeuille et nos partenariats stratgiques, commente Jonathan Dickinson, Prsident du Directoire d'Innate Pharma. La prise de participation de 15 mil
27-Mar-2025 1:00 AM CST - Business Wire Innate Pharma Reports Full Year 2024 Financial Results and Business Update #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today reported its consolidated financial results for the year ending December 31, 2024. The consolidated financial statements are attached to this press release. Our strategy is clear: drive innovation through our ANKET NK-cell engager platform and accelerate our ADC programs. We are making strong clinical progress, with our lead proprietary ANKET, IPH6501 ad
10-Jan-2025 12:00 AM CST - Business Wire Innate Pharma Announces Transformative Strategy to Accelerate Growth #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced its updated strategy for company growth. This comprehensive plan is anchored in three key pillars designed to drive sustainable growth, foster innovation, and deliver transformative therapies to patients worldwide. "Our updated strategy underscores Innate Pharmas unwavering dedication to innovation, collaboration, and delivering transformative th
20-Dec-2024 12:00 AM CST - Business Wire Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that its management will present and host 1x1 meetings at the 43rd Annual J.P. Morgan Healthcare Conference being held on January 13-16, 2025 in San Francisco, CA. Jonathan Dickinson, Chief Executive Officer of Innate Pharma, will represent the Company in a session scheduled Tuesday, January 14, 2025 from 11:15 - 11:55 am PST. Other Executive Boar
13-Nov-2024 12:00 AM CST - Business Wire Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced its business update and financial results for the first nine months of 2024. "Im honored to join Innate Pharma at such a pivotal moment in its evolution, said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. We achieved notable regulatory milestones during the quarter including encouraging initial feedback from the FDA for lacutama
